PetMed Express Earnings Call Transcripts
Fiscal Year 2026
-
Fiscal 2026 saw a 21.1% revenue decline and a $57.3M net loss, but operational improvements, cost reductions, and technology upgrades led to sequential Q4 sales growth and improved gross margin. The board rejected acquisition offers, focusing on long-term independence.
Fiscal Year 2025
-
Q3 saw a 19% sales decline to $53M, but gross margin improved and adjusted EBITDA doubled year-over-year. Strategic cost cuts, digital upgrades, and a marketing reset are underway, with $50M in cash and no debt supporting ongoing transformation.
-
Transformation efforts have modernized operations, rebranded the business as a consumer pet healthcare company, and expanded product offerings. Technology upgrades, cost savings, and new marketing strategies target younger customers and recurring revenue growth. Partnerships and community engagement further strengthen the ecosystem.
-
Second quarter sales declined 16% year-over-year to $60 million, but gross margin and net income improved due to cost reductions and operational efficiencies. Marketing investment will increase in the second half to drive new customer growth, though a more promotional environment may pressure margins.
-
Q1 FY2025 saw a 13% sales decline and margin compression due to macro headwinds and tech disruptions, but operational improvements, cost savings, and digital initiatives are driving early signs of stabilization and margin recovery. Cash remains strong at $53 million, debt-free.
Fiscal Year 2024
-
The company is undergoing a digital and operational transformation, expanding its product mix beyond Rx to include OTC and food, and leveraging data and AI for customer engagement. Cost efficiencies, a revamped C-suite, and new partnerships are driving growth, with a focus on private label, autoship, and deeper veterinary engagement.
-
Q4 sales grew 6.6% year-over-year to $66.5M, driven by the PetCareRx acquisition, but gross margin declined and net loss widened to $5M. Strategic focus is on brand consolidation, technology upgrades, and expanding recurring revenue, supported by strong liquidity and new executive leadership.